Atropos Health, a Palo Alto, CA-based pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, raised $33m in Series B funding.
The round was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck GHI Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.
on the heels of the adoption of its Generative AI platform (GENEVA OSTM) by healthcare institutions, data platforms, research institutions, Life Sciences companies and more.
Founded in 2019 as a spin-out of the “Green Button” technology developed at Stanford University by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., Atropos Health is the developer of GENEVA OSTM, the operating system for rapid healthcare evidence across a network of real-world data.
Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more.
The company’s portfolio of evidence-generating applications supports whole-person care and value-based performance and has long been utilized by Atropos Health partners including Arcadia. Through Atropos Health, healthcare organizations are able to accelerate appropriate clinical decision-making to drive high-value, low-cost care for patients based on their unique physiology.
FinSMEs
23/05/2024